A post-hoc analysis to assess prognostic factors was performed with the use of patients with EGFR mutations ( exon @ deletion , L@R , G@X , and L@Q ) who were treated with gefitinib in the NEJ@ study , which compared gefitinib with carboplatin-paclitaxel as the first-line therapy .